An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

Completed · Phase 1/Phase 2

Conditions studied: Advanced Cancer

In brief

The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.

Key facts

Study ID

NCT02737475

Run by

Bristol-Myers Squibb

People needed

166

Starts

2016-06-17

Expected to finish

2020-11-02

Last updated by the study team

2022-01-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• For Part 9 (only arm open for enrollment):
• Stage IV metastatic or unresectable triple negative breast cancer (TNBC) with zero or one prior systemic therapies in the advanced metastatic setting
• Participants with < 12 months from receipt of last curative-intent chemotherapy are allowed; curative chemotherapy will be considered first-line therapy
• Prior receipt of chemotherapy in the (neo)adjuvant setting is acceptable, as long as completed greater than 6 months from start of treatment
• Tumor biopsy samples (mandatory pre- and on-treatment biopsies) are required for all participants enrolled
• Must have histologic or cytologic confirmation of a malignancy that is advanced (metastatic, recurrent, refractory, and/or unresectable) with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
• Men and women must agree to follow specific methods of contraception, if applicable

You may not qualify if…

• Must be immunotherapy treatment naïve, including no prior therapy with T cell immune checkpoint blocker (anti-PDL1, anti-PD1). Prior receipt of intralymphatic cytokine therapy (IRX-2) is acceptable (Part 9 only)
• Other active malignancy requiring concurrent intervention
• Prior therapy with any agent specifically targeting T-cell co-stimulation pathways such as anti-OX40 antibody, anti-CD137, anti- glucocorticoid-induced TNFR-related gene (anti-GITR) antibody, and anti-CD27
• Known or underlying medical or psychiatric condition and/or social reason that, in the opinion of the investigator or Sponsor, could make the administration of study drug hazardous to the participant or could adversely affect the ability of the participant to comply with or tolerate the study
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• University Of Colorado — Aurora, Colorado, United States
• Georgetown University Medical Center — Washington D.C., District of Columbia, United States
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Columbia University Medical Center (Cumc) — New York, New York, United States
• Providence Portland Medical Center — Portland, Oregon, United States
• Oregon Health & Science University — Portland, Oregon, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• Cross Cancer Institute — Edmonton, Alberta, Canada
• Local Institution — Ottawa, Ontario, Canada
• Local Institution — Toronto, Ontario, Canada
• Local Institution — Ramat Gan, Israel
• Local Institution — Tel Aviv, Israel
• IRCCS Istituto Nazionale Tumori Milano — Milan, Italy
• Istituto Clinico Humanitas — Rozzano, Italy
• Local Institution — Amsterdam, Netherlands
• Local Institution — Utrecht, Netherlands
• H. Univ. Vall dHebron — Barcelona, Spain
• Fundacion Jimenez Diaz — Madrid, Spain
• Hosp. Univ. Puerta De Hierro — Majadahonda - Madrid, Spain
• Hospital Universitario Virgen De La Victoria — Málaga, Spain
• Clinica Universidad de Navarra — Pamplona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.